T. Varrieur

发表

Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study.

J. Neutel, Jennifer L. Hellawell, W. Sohn, 2022, Clinical therapeutics.

Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study

J. Neutel, Jennifer L. Hellawell, W. Sohn, 2022 .

OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

T. Burns, A. Spira, A. Chiappori, 2022, Journal of Thoracic Oncology.

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Saptarsi M. Haldar, S. Melquist, G. Watts, 2022, Nature Medicine.

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Saptarsi M. Haldar, S. Melquist, Hong Wang, 2022, Nature Medicine.

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

C. Dooms, Melissa L. Johnson, S. Novello, 2023, The Lancet.

MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC

J. Clarke, J. Ruffinelli, E. Felip, 2023, Journal of Thoracic Oncology.

OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

J. Krauss, C. Langer, K. Marrone, 2022, Journal of Thoracic Oncology.